200 related articles for article (PubMed ID: 21781317)
1. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.
Glen H; Mason S; Patel H; Macleod K; Brunton VG
BMC Cancer; 2011 Jul; 11():309. PubMed ID: 21781317
[TBL] [Abstract][Full Text] [Related]
2. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
[TBL] [Abstract][Full Text] [Related]
3. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD.
Wei X; Zhang T; Yao Y; Zeng S; Li M; Xiang H; Zhao C; Cao G; Li M; Wan R; Yang P; Yang J
Exp Eye Res; 2018 Mar; 168():2-11. PubMed ID: 29284110
[TBL] [Abstract][Full Text] [Related]
5. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
[TBL] [Abstract][Full Text] [Related]
6. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
7. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Ogino H; Hanibuchi M; Kakiuchi S; Trung VT; Goto H; Ikuta K; Yamada T; Uehara H; Tsuruoka A; Uenaka T; Wang W; Li Q; Takeuchi S; Yano S; Nishioka Y; Sone S
Mol Cancer Ther; 2011 Jul; 10(7):1218-28. PubMed ID: 21551260
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
9. Arsenite suppresses angiogenesis of vascular endothelial cells mediated by Platelet Derived Growth Factor Receptor-beta.
Wang X; Mou Y; Yue Z; Zhang H; Su X; Wang Y; Li R; Sun X
Environ Toxicol Pharmacol; 2016 Sep; 46():168-173. PubMed ID: 27475902
[TBL] [Abstract][Full Text] [Related]
10. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
11. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
Zhou Y; Chen Y; Tong L; Xie H; Wen W; Zhang J; Xi Y; Shen Y; Geng M; Wang Y; Jiang H; Luo C; Lin L; Ding J
J Cell Mol Med; 2012 Oct; 16(10):2321-30. PubMed ID: 22304225
[TBL] [Abstract][Full Text] [Related]
12. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
13. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
[TBL] [Abstract][Full Text] [Related]
14. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
15. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
16. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
17. Postnatal tendon growth and remodeling require platelet-derived growth factor receptor signaling.
Sugg KB; Markworth JF; Disser NP; Rizzi AM; Talarek JR; Sarver DC; Brooks SV; Mendias CL
Am J Physiol Cell Physiol; 2018 Apr; 314(4):C389-C403. PubMed ID: 29341790
[TBL] [Abstract][Full Text] [Related]
18. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
20. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
